Chenhui Ma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Chenhui Ma has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Linfu Zhou
Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu, China; Institute of Integrative Medicine, Nanjing Medical University, Nanjing, Jiangsu, China
2 shared publications - Linyang Ge
Department of Respiratory, Nanjing Gaochun People’s Hospital, Nanjing, China
2 shared publications - Liuchao Zhang
Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu, China
2 shared publications - Quan He
Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu, China
2 shared publications - Shuanglan Xu
Department of Pulmonary and Critical Care Medicine, The Affiliated Hospital of Yunnan University, Key Laboratory of Respiratory Disease Research of Department of Education of Yunnan Province, 650021 Kunming, Yunnan, China
2 shared publications - Weihua Liu
Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu, China
2 shared publications
Latest Publications
- Open Access
- 13 November 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (22) , 10188
Nrf2 Inhibits CXCL2-Dependent Neutrophil Recruitment to Alleviate Airway Inflammation and Epithelial Barrier Injury in House Dust Mite-Induced Murine Asthma
Neutrophilic asthma represents a severe, often corticosteroid-insensitive asthma subtype with an unmet clinical need for new therapeutic targets. This study aimed to identify key molecular mediators and regulatory pathways involved in neutrophilic airway inflammation through unbiased bioinformatic analysis of public human asthma transcriptomic datasets. Among the identified hub genes, C-X-C motif chemokine ligand 2 (CXCL2), a critical driver of neutrophil recruitment and pulmonary inflammation, was prioritized for mechanistic follow-up. We combined HDM-induced murine asthma models, dual-luciferase reporter assays and ChIP-qPCR to characterize the transcriptional regulation of CXCL2. Our results demonstrate that transcription factor Nrf2 directly binds the CXCL2 promoter and suppresses CXCL2 transcription. Genetic deletion of Nrf2 exacerbates neutrophil infiltration, airway inflammation and epithelial barrier disruption accompanied by increased CXCL2 expression, whereas pharmacological Nrf2 activation by MOTS-c downregulates CXCL2 and alleviates neutrophilic airway inflammation. Collectively, this work identifies the Nrf2/CXCL2 axis as a candidate regulatory pathway in experimental neutrophilic asthma, providing a potential target for further translational investigation.
- 13 November 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (22) , 10188
Open AccessNrf2 Inhibits CXCL2-Dependent Neutrophil Recruitment to Alleviate Airway Inflammation and Epithelial Barrier Injury in House Dust Mite-Induced Murine Asthma
Neutrophilic asthma represents a severe, often corticosteroid-insensitive asthma subtype with an unmet clinical need for new therapeutic targets. This study aimed to identify key molecular mediators and regulatory pathways involved in neutrophilic airway inflammation through unbiased bioinformatic analysis of public human asthma transcriptomic datasets. Among the identified hub genes, C-X-C motif chemokine ligand 2 (CXCL2), a critical driver of neutrophil recruitment and pulmonary inflammation, was prioritized for mechanistic follow-up. We combined HDM-induced murine asthma models, dual-luciferase reporter assays and ChIP-qPCR to characterize the transcriptional regulation of CXCL2. Our results demonstrate that transcription factor Nrf2 directly binds the CXCL2 promoter and suppresses CXCL2 transcription. Genetic deletion of Nrf2 exacerbates neutrophil infiltration, airway inflammation and epithelial barrier disruption accompanied by increased CXCL2 expression, whereas pharmacological Nrf2 activation by MOTS-c downregulates CXCL2 and alleviates neutrophilic airway inflammation. Collectively, this work identifies the Nrf2/CXCL2 axis as a candidate regulatory pathway in experimental neutrophilic asthma, providing a potential target for further translational investigation.
- Open Access
- 23 September 2022
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (38) , e30661
Identification of potential biomarkers and pathogenesis in neutrophil-predominant severe asthma: A comprehensive bioinformatics analysis
Background: Airway neutrophilia has been associated with asthma severity and asthma exacerbations. This study attempted to identify biomarkers, pathogenesis, and therapeutic molecular targets for severe asthma in neutrophils using bioinformatics analysis. Methods: Fifteen healthy controls and 3 patients with neutrophilic severe asthma were screened from the Gene Expression Omnibus (GEO) database. Based on the analysis of differentially expressed genes (DEGs), functional and pathway enrichment analyses, gene set enrichment analysis, protein–protein interaction network construction, and analysis were performed. Moreover, small-molecule drug candidates have also been identified. Results: Three hundred and three upregulated and 59 downregulated genes were identified. Gene ontology function enrichment analyses were primarily related to inflammatory response, immune response, leukocyte migration, neutrophil chemotaxis, mitogen-activated protein kinase cascade, Jun N-terminal kinase cascade, I-kappaB kinase/nuclear factor-κB, and MyD88-dependent toll-like receptor signaling pathway. Pathway enrichment analyses and gene set enrichment analysis were mainly involved in cytokine-cytokine receptor interaction, the TNF signaling pathway, leukocyte transendothelial migration, and the NOD-like receptor signaling pathway. Furthermore, 1 important module and 10 hub genes (CXCL8, TLR2, CXCL1, ICAM1, CXCR4, FPR2, SELL, PTEN, TREM1, and LEP) were identified in the protein–protein interaction network. Moreover, indoprofen, mimosine, STOCK1N-35874, trapidil, iloprost, aminoglutethimide, ajmaline, levobunolol, ethionamide, cefaclor, dimenhydrinate, and bethanechol are potential drugs for the treatment of neutrophil-predominant severe asthma. Conclusion: This study identified potential biomarkers, pathogenesis, and therapeutic molecular targets for neutrophil-predominant severe asthma.
- 23 September 2022
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (38) , e30661
Open AccessIdentification of potential biomarkers and pathogenesis in neutrophil-predominant severe asthma: A comprehensive bioinformatics analysis
Background: Airway neutrophilia has been associated with asthma severity and asthma exacerbations. This study attempted to identify biomarkers, pathogenesis, and therapeutic molecular targets for severe asthma in neutrophils using bioinformatics analysis. Methods: Fifteen healthy controls and 3 patients with neutrophilic severe asthma were screened from the Gene Expression Omnibus (GEO) database. Based on the analysis of differentially expressed genes (DEGs), functional and pathway enrichment analyses, gene set enrichment analysis, protein–protein interaction network construction, and analysis were performed. Moreover, small-molecule drug candidates have also been identified. Results: Three hundred and three upregulated and 59 downregulated genes were identified. Gene ontology function enrichment analyses were primarily related to inflammatory response, immune response, leukocyte migration, neutrophil chemotaxis, mitogen-activated protein kinase cascade, Jun N-terminal kinase cascade, I-kappaB kinase/nuclear factor-κB, and MyD88-dependent toll-like receptor signaling pathway. Pathway enrichment analyses and gene set enrichment analysis were mainly involved in cytokine-cytokine receptor interaction, the TNF signaling pathway, leukocyte transendothelial migration, and the NOD-like receptor signaling pathway. Furthermore, 1 important module and 10 hub genes (CXCL8, TLR2, CXCL1, ICAM1, CXCR4, FPR2, SELL, PTEN, TREM1, and LEP) were identified in the protein–protein interaction network. Moreover, indoprofen, mimosine, STOCK1N-35874, trapidil, iloprost, aminoglutethimide, ajmaline, levobunolol, ethionamide, cefaclor, dimenhydrinate, and bethanechol are potential drugs for the treatment of neutrophil-predominant severe asthma. Conclusion: This study identified potential biomarkers, pathogenesis, and therapeutic molecular targets for neutrophil-predominant severe asthma.
- Open Access
- 29 January 2022
- Published by Elsevier in Complementary Therapies in Medicine
- Vol. 65, 102809
Efficacy of Liuzijue Qigong in patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis
- 29 January 2022
- Published by Elsevier in Complementary Therapies in Medicine
- Vol. 65, 102809
Open AccessEfficacy of Liuzijue Qigong in patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis
- 3 December 2015
- Published by Springer Nature in Tumor Biology
- Vol. 37 (2) , 1437-1444
The growth arrest-specific transcript 5 (GAS5): a pivotal tumor suppressor long noncoding RNA in human cancers
Long noncoding RNAs (lncRNAs), which refer to a group of RNAs with length more than 200 nucleotides and limited protein-coding potential, play a widespread role in regulating biological processes, such as cell differentiation, proliferation, apoptosis, and migration. LncRNAs are dysregulated in multiple cancers, playing an either oncogenic or tumor-suppressive role. LncRNA GAS5 is a recently identified tumor suppressor involved in several cancers, like breast cancer, prostate cancer, lung cancer, and colorectal cancer. The low-expression pattern confers tumor cells elevated capacity of proliferation and predicts poorer prognosis. Existing studies mirror that lncRNA GAS5 promises to be a novel diagnostic biomarker, therapy target, as well as prognostic biomarker. In this review, we will summarize the current knowledge about this vital lncRNA, from its discovery, characteristics, and biological function to molecular mechanism in various neoplasms.
- 3 December 2015
- Published by Springer Nature in Tumor Biology
- Vol. 37 (2) , 1437-1444
The growth arrest-specific transcript 5 (GAS5): a pivotal tumor suppressor long noncoding RNA in human cancers
Long noncoding RNAs (lncRNAs), which refer to a group of RNAs with length more than 200 nucleotides and limited protein-coding potential, play a widespread role in regulating biological processes, such as cell differentiation, proliferation, apoptosis, and migration. LncRNAs are dysregulated in multiple cancers, playing an either oncogenic or tumor-suppressive role. LncRNA GAS5 is a recently identified tumor suppressor involved in several cancers, like breast cancer, prostate cancer, lung cancer, and colorectal cancer. The low-expression pattern confers tumor cells elevated capacity of proliferation and predicts poorer prognosis. Existing studies mirror that lncRNA GAS5 promises to be a novel diagnostic biomarker, therapy target, as well as prognostic biomarker. In this review, we will summarize the current knowledge about this vital lncRNA, from its discovery, characteristics, and biological function to molecular mechanism in various neoplasms.